{
    "id": 1787,
    "fullName": "AR act mut",
    "impact": "unknown",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "AR act mut indicates that this variant results in a gain of function in the Ar protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 367,
        "geneSymbol": "AR",
        "terms": [
            "AR",
            "AIS",
            "AR8",
            "DHTR",
            "HUMARA",
            "HYSP1",
            "KD",
            "NR3C4",
            "SBMA",
            "SMAX1",
            "TFM"
        ]
    },
    "variant": "act mut",
    "createDate": "09/18/2014",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6706,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Galeterone treatment resulted in more than 50% decrease of PSA in 86% (6/7) of castration-resistant prostate cancer patients harboring AR C-terminal truncation mutations, compared to 57% (31/54) in patients without the mutation (J Clin Oncol 34, 2016 (suppl; abstr 5064)).",
            "molecularProfile": {
                "id": 1778,
                "profileName": "AR act mut"
            },
            "therapy": {
                "id": 1508,
                "therapyName": "galeterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5755,
                    "pubMedId": null,
                    "title": "Galeterone in treatment-na\u00efve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_170683.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1778,
            "profileName": "AR act mut",
            "profileTreatmentApproaches": [
                {
                    "id": 129,
                    "name": "Hormone - Anti-androgens",
                    "profileName": "AR act mut"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}